GILD Jun 2024 61.000 put
| Previous close | 0.4600 |
| Open | 0.2700 |
| Bid | 0.2300 |
| Ask | 0.2500 |
| Strike | 61.00 |
| Expiry date | 2024-06-14 |
| Day's range | 0.2700 - 0.3700 |
| Contract range | N/A |
| Volume | |
| Open interest | 498 |
Business WireGilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
FOSTER CITY, Calif., June 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people living with PBC who participated in any prior clinical studies of seladelpar (legacy studies) and participants from
ZacksThe Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR are part of the Zacks top Analyst Blog.
Insider MonkeyHedge Funds are Bullish on This Gene Therapy Stock
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ:GILD), which is one of the best gene therapy stocks to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. […]
